Data on lipid levels of 2, 3,7, in the general population in the United States, Canada, Germany, and France over the past 30 years were compiled from the literature. Mean lipid levels of TCDD exhibited a steady decrease by nearly a factor of 10 over this time period, with lipid -adjusted TCDD levels in 2000 about 2 parts per trillion ( ppt ). Pharmacokinetic modeling using a one -compartment model indicated that absorbed intake levels of TCDD must have decreased by more than 95% from levels in 1972 to result in the observed decrease in human lipid levels, with the bulk of this decrease occurring before 1980. Based on this modeling and the pharmacokinetic properties of TCDD in humans, we conclude that mean levels of TCDD in the general population are likely to decrease further over the next 15 years, to between 0.5 and 1 ppt, even if intake levels do not decrease further. Fewer data over a shorter time period are available for other dioxin and furan congeners in human lipid, but these data indicate substantial decreases as well, with general population TEQ lipid levels currently at least fourfold lower than in 1970 and still decreasing. Food sampling data are limited, but support these trends.